Oxurion NV Logo

Oxurion NV

OXUR | BR

Overview

Corporate Details

ISIN(s):
BE0974487192
LEI:
549300VWY8KVDFKLDM59
Country:
Belgium
Address:
Gaston Geenslaan 1, 3001 Heverlee
Sector:
Professional, scientific and technical activities
Industry:
Research and experimental development on natural sciences and engineering

Description

Oxurion NV is a biopharmaceutical company undergoing a strategic transition. Historically, the company focused on pioneering treatments for retinal diseases, such as Geographic Atrophy (GA) and Age-related Macular Degeneration (AMD), using innovative approaches including a CRISPR-based target discovery platform. Following a recent strategic shift, Oxurion has ended its internal R&D program in Geographic Atrophy to refocus its business on providing Contract Research Organization (CRO) services to the life sciences sector.

Social Media

Stop Scraping. Start Analyzing.

You're viewing a fraction of the data available for Oxurion NV. Get complete, real-time, and AI-ready data via the API the pros use.

Get Instant API & Bulk Data Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2025-08-07 18:00
Legal Proceedings Report
OXUR-New-Development-Strategy-EN-20250806.pdf
English 195.7 KB
2025-08-07 18:00
Regulatory News Service
FR_OXURION_PR_New-Development-Strategy_SD_20250806.pdf
French 133.2 KB
2025-08-07 18:00
Earnings Release
OXUR-New-Development-Strategy-NL-20250806.pdf
Dutch 213.8 KB
2025-08-07 18:00
Major Shareholding Notification
OXUR-Transparency-Notification-EN-20250807.pdf
English 479.6 KB
2025-08-07 18:00
Major Shareholding Notification
OXUR-Transparency-Notification-NL-20250807.pdf
English 506.8 KB
2025-08-04 08:30
M&A Activity
OXURION_PR_Closing_Acquisition_UK.pdf
English 200.6 KB
2025-08-04 08:30
M&A Activity
OXURION_PR_Closing_Acquisition_FR.pdf
French 157.5 KB
2025-08-04 08:30
M&A Activity
OXURION_PR_Closing_Acquisition_NL.pdf
Dutch 246.7 KB
2025-07-30 18:00
Major Shareholding Notification
OXUR-Transparency-Notification-EN-20250723.pdf
English 358.7 KB
2025-07-30 18:00
Major Shareholding Notification
OXUR-Transparency-Notification-NL-20250723.pdf
Dutch 381.8 KB
2025-07-30 18:00
Major Shareholding Notification
OXUR-Transparency-Notification-EN-20250730.pdf
English 360.1 KB
2025-07-30 18:00
Major Shareholding Notification
OXUR-Transparency-Notification-NL-20250730.pdf
Dutch 383.3 KB
2025-07-30 18:00
Share Issue/Capital Change
OXUR-PR_Voting-rights-ENG_20250730.pdf
English 281.6 KB
2025-07-30 18:00
Declaration of Voting Results & Voting Rights Announcements
OXUR-PR_Voting-rights-NED_20250730.pdf
Dutch 405.2 KB
2025-07-25 18:00
Declaration of Voting Results & Voting Rights Announcements
OXUR-PR_Voting-rights-ENG_20250725.pdf
English 281.3 KB

Automate Your Workflow. Get a real-time feed of all Oxurion NV filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Oxurion NV via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2022-03-07 Bareldam SA Close relation Buy 1,180,555 1,700,000.00 EUR
2021-09-30 Lavinia D. Clay 2009 Revocable Trust Close relation Other 2,766,337 5,601,002.52 EUR

Peer Companies

Company Country Ticker View
Plantarc Bio Ltd. Logo
Agritech firm using gene discovery & editing to improve crop yield, resilience, and pest control.
Israel PLNT
POLAREAN IMAGING PLC Logo United States of America POLX
Poltreg S.A. Logo
Develops T-regulatory cell (Treg) therapies for autoimmune diseases like diabetes and MS.
Poland PTG
POOLBEG PHARMA PLC Logo
AI-led biopharma developing drugs for high-need diseases like CRS and metabolic disorders.
United Kingdom POLB
Poxel Logo
Biopharma developing treatments for metabolic diseases like NASH, with a marketed drug for diabetes.
France POXEL
PROTEOME SCIENCES PLC Logo
CRO providing proteomics services & TMT® tags to biopharma for drug discovery & biomarkers.
United Kingdom PRM
PROVEXIS PLC Logo
Develops & licenses Fruitflow®, a patented ingredient for heart health in food & supplements.
United Kingdom PXS
Psych Capital Plc Logo
Develops psilocybin-based therapies for anorexia nervosa and other mental health conditions.
United Kingdom PSY
Pure Biologics S.A. Logo
Develops novel antibody and aptamer drugs for immuno-oncology and autoimmunity.
Poland PUR
Puretech Health PLC Logo United States of America PRTC